NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink
Because the needle stays in the fatty layer, there is less chance of catching a nerve or a blood vessel than with a deeper injection, which is one reason some clinicians prefer it for maintenance dosing
In adipose models, reduced NNMT activity has been linked with smaller adipocyte size and diminished fat depots, suggesting a potential role for this inhibitor in fat mass modulation under research conditions
It has also been shown to lower homocysteine levels, a molecule linked to inflammation and cognitive decline, with longitudinal studies linking optimal B12 levels with improved cognitive function, mood and reduced risk of neurodegenerative disease
As of 2026, retatrutide has not received marketing authorisation from the MHRA or EMA and is only accessible within authorised clinical trials